Purui Bio Completes Over RMB 100 Million in New Financing to Accelerate AI-Driven Drug Discovery and Innovation

Recently, Precision Scientific announced the completion of a new round of financing, with a total amount exceeding 100 million yuan. This round of financing was jointly led by Salubris, Guangdong Investment Capital, and ShenHong Zhongheng Fund, with existing shareholders Jingu Hui Feng and Ju Yi Investment participating in the investment.

Precision Scientific has long been dedicated to the "biology + AI" field, continuously exploring applications that combine biology with AI and computational methods. The company has developed AIBERT, an AI-driven system for mining massive multi-omics data in new drug research and development. By analyzing multi-omics data, it provides decision support for differentiated strategies in new drug development, including innovative target discovery/evaluation, indication selection, novel biomarker discovery, resistance mechanism research, and combination therapy exploration. The company also addresses unmet clinical testing needs by analyzing and mining omics data to discover multiple innovative disease biomarkers. Based on these novel biomarkers, Precision Scientific collaborates with several academicians and clinical experts to develop world-leading testing products (focusing on gynecological oncology). Additionally, the company has developed ProT-Diff, a generative AI algorithm that combines large protein models with diffusion models to design and optimize peptides/proteins, achieving excellent results.

The company provides "dry and wet combination" central laboratory services, featuring innovative biomarker discovery. It has further built an international-level central laboratory with CAP and CLIA certifications, thereby offering pharmaceutical enterprise partners one-stop biomarker and bioanalytical solutions.

This round of financing will focus on supporting Precision Scientific in its deep layout in the "biology + AI" field, accelerating AI-driven drug research and development and innovative breakthroughs. This includes the continuous upgrading of the AIBERT multi-omics data mining platform, the ProT-Diff peptide AI design platform, and the "dry-wet combination" central laboratory, as well as the research and development and regulatory approval of innovative testing products.

As AI technology continues to make breakthroughs, the traditional drug research and development model is undergoing profound changes. Precision Scientific, based on "biology + AI," persists in innovation and continuous cooperation with the industry, assisting in the R&D upgrade and internationalization of China's pharmaceutical and biotechnology industries.

Duan Feng, General Manager of the Investment Department at Salubris Pharmaceuticals, stated: "This transaction will help Salubris further enhance R&D efficiency, identify new pathways to address unresolved clinical issues, and accelerate the development of cardio-renal metabolism drugs. It is expected to strengthen the company's overall capabilities in new drug development and provide new avenues for innovative drug research, aligning with industry trends and the company’s long-term strategy."

Shenzhen Salubris Pharmaceuticals Co., Ltd. was established in November 1998. It is an innovation-driven pharmaceutical enterprise based in China, with a global outlook, integrating research, production, and sales. The company is a leader in the field of cardiovascular and other chronic disease treatments. Deeply committed to the chronic disease sector, safeguarding life and health, it has developed three innovative segments: high-end chemical drugs, biomedicine, and medical devices. With excellent product quality, professional evidence-based medical data, and a comprehensive product line layout, it provides global patients with all-around treatment solutions.

Guangdong Investment Capital (GIC) was established in 2017 as a professional fund investment management platform and market-oriented equity investment entity under the Guangxi Investment Group. It is the first state-owned equity investment institution in Guangxi to receive a AA+ credit rating in the capital market. GIC adheres to the principle of "focusing on industries and serving Guangxi," deepening the implementation of a business model that integrates "mother fund + direct investment + industrial operations + management consulting." The company invests in five strategic emerging industries—new energy, new materials, next-generation information technology, advanced manufacturing, and pharmaceuticals and healthcare—as well as Guangxi's distinctive and advantageous industries. GIC aims to become Guangxi’s strategic emerging industry investment holding platform and government fund investment management platform, leading the transformation of traditional industries and accelerating the development of new productive forces. As of March 2025, GIC has cumulatively invested and managed over 99.5 billion yuan, participating in the investment and management of 102 funds. It has received multiple industry accolades, including being listed on Zero2IPO's "Top 50 State-Owned Investment Institutions in China for 2024, 2023, and 2021" (the first state-owned equity investment institution from Guangxi to be featured).

Precision Scientific is a platform company driven by "multi-omics + AI" to provide innovative pharmaceutical R&D services.

The company has built the advanced AIBERT platform, which provides leading pharmaceutical companies with globally competitive innovative target evaluation and clinical development strategy formulation services (indication selection, novel biomarker discovery, drug resistance mechanism research, and combination therapy exploration) by mining massive multi-omics data. It also extends its services to central laboratory testing, companion diagnostic development, and more. Meanwhile, the company’s generative AI algorithm, ProT-Diff, combines large biological models with diffusion models to design functional molecular sequences, including protein/peptide design and modification. Currently, the company has formed deep collaborations with several leading domestic and international pharmaceutical and biotech companies, facilitating the R&D and approval of multiple new drugs.

The company also relies on the technical advantages of "multi-omics + AI" to discover innovative disease biomarkers, develop first-in-China/international detection products for clinical use, and advance the clinical practice of precision medicine.